Research Article| Volume 37, ISSUE 6, P1280-1291, June 01, 2015

Download started.


Asthma Treatments and Mental Health Visits After a Food and Drug Administration Label Change for Leukotriene Inhibitors



      In 2009, the US Food and Drug Administration (FDA) mandated a label change for leukotriene inhibitors (LTIs) to include neuropsychiatric adverse events (eg, depression and suicidality) as a precaution. This study investigated how this label change affected the use of LTIs and other asthma controller medications, mental health visits, and suicide attempts.


      We analyzed data (2005-2010) from 5 large health plans in the US Population-Based Effectiveness in Asthma and Lung Diseases (PEAL) Network. The study cohort included children and adolescents (n = 30,000), young adults (n = 20,000), and adults (n = 90,000) with asthma. We used interrupted time series to examine changes in rates of LTI dispensings, non-LTI dispensings, mental health visits, and suicide attempts (using a validated algorithm based on a combination of diagnoses of injury or poisoning and psychiatric conditions).


      The label change was associated with abrupt reductions in LTI use among all age groups (relative reductions of 8.3%, 15.1%, and 6.0% among adolescents, young adults, and adults, respectively, compared with expected rates at 1 year after the warnings). Although we detected immediate offset increases in non-LTI asthma medication use, these increases were not sustained among adolescents and young adults. There were small increases in mental health visits among LTI users.


      The FDA label change for LTIs communicated possible risk of neuropsychiatric events. Communication and enhanced awareness may have increased reporting of mental health symptoms among young adults and adults. It is important to assess intended and unintended consequences of FDA warnings and label changes.

      Key words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Clinical Therapeutics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Gibbons R.D.
        • Mann J.J.
        Strategies for quantifying the relationship between medications and suicidal behaviour: what has been learned?.
        Drug Saf. 2011; 34: 375-395
        • Mechcatie E.
        FDA Panel Supports Retaining Chantix Boxed Warning for Now.
        Chest Physician. 2014;
      1. FDA. Early Communication About an Ongoing Safety Review of Montelukast (Singulair). Accessed April 15, 2015.

      2. FDA. Updated Information on Leukotriene Inhibitors: Montelukast (marketed as Singulair), Zafirlukast (marketed as Accolate), and Zileuton (marketed as Zyflo and Zyflo CR). Accessed April 15, 2015.

        • Tse S.M.
        • Li L.
        • Butler M.G.
        • et al.
        Statin exposure is associated with decreased asthma-related emergency department visits and oral corticosteroid use.
        Am J Respir Crit Care Med. 2013; 188: 1076-1082
        • Li L.
        • Vollmer W.M.
        • Butler M.G.
        • et al.
        A comparison of confounding adjustment methods for assessment of asthma controller medication effectiveness.
        Am J Epidemiol. 2014; 179: 648-659
        • Fung V.
        • Graetz I.
        • Galbraith A.
        • et al.
        Financial barriers to care among low-income children with asthma: health care reform implications.
        JAMA Pediatr. 2014; 168: 649-656
        • Wagner A.K.
        • Soumerai S.B.
        • Zhang F.
        • et al.
        Segmented regression analysis of interrupted time series studies in medication use research.
        J Clin Pharm Ther. 2002; 27: 299-309
        • Adams A.S.
        • Zhang F.
        • LeCates R.F.
        • et al.
        Prior authorization for antidepressants in Medicaid: effects among disabled dual enrollees.
        Arch Intern Med. 2009; 169: 750-756
        • Lu C.Y.
        • Soumerai S.B.
        • Ross-Degnan D.
        • et al.
        Unintended impacts of a Medicaid prior authorization policy on access to medications for bipolar illness.
        Med Care. 2010; 48: 4-9
        • Lu C.Y.
        • Law M.R.
        • Soumerai S.B.
        • et al.
        Impact of prior authorization on the use and costs of lipid-lowering medications among Michigan and Indiana dual enrollees in Medicaid and Medicare: results of a longitudinal, population-based study.
        Clin Ther. 2011; 33: 135-144
        • Lu C.Y.
        • Zhang F.
        • Lakoma M.D.
        • et al.
        Changes in antidepressant use by young people and suicidal behavior after FDA warnings and media coverage: quasi-experimental study.
        BMJ. 2014; 348: g3596
        • Wu A.C.
        • Smith L.
        • Bokhour B.
        • et al.
        Racial/ethnic variation in parent perceptions of asthma.
        Ambul Pediatr. 2008; 8: 89-97
        • Wu A.C.
        • Li L.
        • Fung V.
        • et al.
        Use of leukotriene receptor antagonists are associated with similar risk of asthma exacerbations as inhaled corticosteroids (In press).
        J Allergy Clin Immunol Pract. 2014; 2: 607-613
      3. Butler M, Zhou E, Zhang F, et al. Report of the Impact of 2010 FDA Regulatory Actions on LABA Medication Use. Accessed April 15, 2015.

        • Crosby A.E.
        • Han B.
        • Ortega L.A.G.
        • et al.
        Suicidal thoughts and behaviors among adults aged ≥18 years-United States, 2008-2009.
        MMWR Surveill Summ. 2011; 60: SS-13
        • Goldman H.H.
        • Frank R.G.
        • Burnam M.A.
        • et al.
        Behavioral health insurance parity for federal employees.
        N Engl J Med. 2006; 354: 1378-1386
        • Patrick A.R.
        • Miller M.
        • Barber C.W.
        • et al.
        Identification of hospitalizations for intentional self-harm when E-codes are incompletely recorded.
        Pharmacoepidemiol Drug Saf. 2010; 19: 1263-1275
        • Lu C.Y.
        • Stewart C.
        • Ahmed A.T.
        • et al.
        How complete are E-codes in commercial plan claims databases?.
        Pharmacoepidemiol Drug Saf. 2014; 23: 218-220
        • Zhang F.
        • Wagner A.K.
        • Soumerai S.B.
        • et al.
        Methods for estimating confidence intervals in interrupted time series analyses of health interventions.
        J Clin Epidemiol. 2009; 62: 143-148
        • Schumock G.T.
        • Stayner L.T.
        • Valuck R.J.
        • et al.
        Risk of suicide attempt in asthmatic children and young adults prescribed leukotriene-modifying agents: a nested case-control study.
        J Allergy Clin Immunol. 2012; 130: 368-375
        • Foxhall K.
        Adverse effects of montelukast examined by FDA's Pediatric Advisory Committee.
        Contemp Pediatr. 2014; ( Accessed April 15, 2015)
        • Yong P.L.
        • Bigman C.
        • Flynn D.N.
        • et al.
        Messages about black-box warnings: a comparative analysis of reports from the FDA and lay media in the US.
        Drug Saf. 2009; 32: 1147-1157
        • Dal Pan G.J.
        Communicating the risks of medicines: time to move forward.
        Med Care. 2012; 50: 463-465
        • Dusetzina S.B.
        • Higashi A.S.
        • Dorsey E.R.
        • et al.
        Impact of FDA drug risk communications on health care utilization and health behaviors: a systematic review.
        Med Care. 2012; 50: 466-478